| Not Yet Recruiting | Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients With Inflammatory Bow NCT06794944 | Brigham and Women's Hospital | Phase 4 |
| Not Yet Recruiting | Pilot Trial of Xylitol for C. Difficile De-Colonization in Patients With Inflammatory Bowel Disease NCT06799039 | Brigham and Women's Hospital | EARLY_Phase 1 |
| Not Yet Recruiting | Xylitol Use for Decolonization of C. Difficile in Patients With IBD NCT05852587 | Brigham and Women's Hospital | Phase 1 |
| Not Yet Recruiting | Fecal Microbiota Transplantation in an Expanded Ulcerative Colitis Population NCT07401680 | University of Alberta | Phase 1 |
| Recruiting | Clostridioides Difficile: Understanding Responses and Treatment Effects NCT07374094 | Umeå University | — |
| Recruiting | Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody NCT07285213 | AstraZeneca | Phase 2 |
| Not Yet Recruiting | Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement NCT06884748 | Medical College of Wisconsin | EARLY_Phase 1 |
| Recruiting | Secondary Prevention of Clostridioides Difficile Using Vancomycin NCT06979609 | McGill University Health Centre/Research Institute of the McGill University Health Centre | Phase 2 / Phase 3 |
| Not Yet Recruiting | STOP-CDI: Efficacy of Fecal Microbiota Transplantation vs Fidaxomicin vs Vancomycin in Treating and Preventing NCT07120490 | Medical University of Warsaw | N/A |
| Not Yet Recruiting | A Flexible Clinical Trial to Test if Freeze-dried Fecal Microbiota Therapy Helps Treat Diarrhea-predominant Ir NCT06948461 | PharmaPlanter Technologies Inc | Phase 2 |
| Not Yet Recruiting | CMTS0929 for Clostridioides Difficile Infection NCT06836427 | The Second Hospital of Nanjing Medical University | EARLY_Phase 1 |
| Completed | Safety and Tolerability of AZD5148 in Japanese Participants NCT06639997 | AstraZeneca | Phase 1 |
| Recruiting | Prevention of Clostridium Difficile Infections Using Lactobacillus Plantarum 299v Strain in Nephrology and Tra NCT06859437 | Medical University of Silesia | N/A |
| Recruiting | LMN-201 for Prevention of C. Difficile Infection Recurrence NCT05330182 | Lumen Bioscience, Inc. | Phase 2 / Phase 3 |
| Recruiting | Study of Clostridioides Difficile in Infants NCT06788769 | Westlake University | — |
| Recruiting | VE303 for Prevention of Recurrent Clostridioides Difficile Infection NCT06237452 | Vedanta Biosciences, Inc. | Phase 3 |
| Recruiting | Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infec NCT06306014 | Hospices Civils de Lyon | Phase 1 / Phase 2 |
| Recruiting | Lyophilized Fecal Microbiome Transfer vs. Vancomycin Monotherapy for Primary Clostridioides Difficile Infectio NCT05709184 | Rambam Health Care Campus | N/A |
| Unknown | Clostridioides Difficile Colonisation NCT05693077 | Leiden University Medical Center | Phase 1 |
| Unknown | L. Plantarum 299v and Gut Microbiome, Diarrhoea, and Clostridioides Difficile Infection in Colorectal Cancer P NCT06019312 | Medical University of Gdansk | N/A |
| Recruiting | Washed Microbiota Transplantation for Clostridioides Difficile Infection NCT06106698 | The Second Hospital of Nanjing Medical University | — |
| Recruiting | Fecal Microbiota Transplantation in Clostridioides Difficile Infection First Episode and First Recurrence NCT05266807 | Benoit Guery | Phase 3 |
| Recruiting | Evaluation of GeoHAI Implementation NCT05612672 | Ohio State University | N/A |
| Completed | Oral Vancomycin Vs Placebo in the Prevention of Recurrence of Clostridioides Difficile's Infection NCT05320068 | Julia Orígüen | Phase 3 |
| Completed | Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection NCT05304715 | Hellenic Institute for the Study of Sepsis | Phase 2 |
| Completed | Effect of Oral Microbiota on MDRO Decolonization NCT07496502 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | Phase 1 / Phase 2 |
| Recruiting | FMT in Initial CDI NCT05257538 | Turku University Hospital | N/A |
| Unknown | Fecal Microbiota Transplantation for Early Clostridioides Difficile Infection NCT04885946 | Christian Hvas | N/A |
| Recruiting | Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT) NCT04305769 | University of Virginia | Phase 2 |
| Terminated | Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects NCT04802837 | Summit Therapeutics | Phase 3 |
| Completed | Addressing Personalized Needs in Clostridioides Difficile Infection NCT04725123 | Hellenic Institute for the Study of Sepsis | N/A |
| Completed | Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection NCT04781387 | Crestone, Inc | Phase 2 |
| Withdrawn | The Role of Mucosal Microbiome in the Development, Clearance and Recurrence of Clostridioides Difficile Infect NCT04679324 | Mayo Clinic | — |
| Completed | The Role of Mucosal Microbiome in Recurrence of Clostridioides Difficile Infection NCT04675723 | Mayo Clinic | — |
| Completed | The Characteristics and Role of Mucosal Microbiome After Treatment of Clostridioides Difficile Infection NCT04668014 | Mayo Clinic | — |
| Terminated | Ursodeoxycholic Acid in C. Difficile Infection NCT05526807 | Nottingham University Hospitals NHS Trust | N/A |
| Completed | Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection NCT03788434 | Vedanta Biosciences, Inc. | Phase 2 |
| Completed | Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection NCT03595553 | Summit Therapeutics | Phase 3 |
| Completed | ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection NCT03183141 | Seres Therapeutics, Inc. | Phase 3 |
| Recruiting | Rescue Fecal Microbiota Transplantation for National Refractory Intestinal Infections NCT03895593 | The Second Hospital of Nanjing Medical University | — |
| Approved For Marketing | Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Clostridioides Difficile Infectio NCT02437500 | Seres Therapeutics, Inc. | — |